




RealRate

PHARMACEUTICAL 2024

XOMA Royalty Corp
Rank 155 of 309



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of XOMA Royalty Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of XOMA Royalty Corp compared to the market average is the variable Assets, increasing the Economic Capital Ratio by 72% points. The greatest weakness of XOMA Royalty Corp is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 134% points.

The company's Economic Capital Ratio, given in the ranking table, is 214%, being 1.1% points above the market average of 213%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	169,313	Assets	234,301
Cost of Goods Sold	0	Liabilities	145,580
Intangible Assets	0	Expenses	47,175
Liabilities, Current	19,499	Revenues	4,758
Liabilities, Non-Current	118,853	Stockholders Equity	88,721
Other Assets	64,963	Net Income	-40,831
Other Compr. Net Income	0	Comprehensive Net Income	-40,831
Other Expenses	21,426	BaseVar	216,700
Other Liabilities	7,228	ECR before LimitedLiability	80%
Other Net Income	1,586	Economic Capital Ratio	214%
Other Revenues	4,758		
Property and Equipment	25		
Research and Development	143		
Selling, General and Administrative Expense	25,606		